 Granulocyte-macrophage colony-stimulating factor neutropenia combined interferon alfa zidovudine treatment immune deficiency syndrome-associated Kaposi sarcoma combined use zidovudine ZDV interferon IFN antiretroviral antitumor potential benefit treatment immune deficiency syndrome AIDS Kaposi sarcoma KS clinical use combination myelotoxicity agents results phase I/II study granulocyte-macrophage colony-stimulating factor GM-CSF KS patients neutropenic ZDV mg/d IFN U/d Nineteen patients absolute neutrophil count ANC cells cubic millimeter GM-CSF All prompt increase ANC patients GM-CSF/ZDV/IFN improved end study ANC ZDV/IFN group rate tumor response end study cell count improvement hematologic variable use GM-CSF increased toxicity particular change serum human immunodeficiency virus HIV antigen Tumor response assessable patients overall high-risk characteristics responding patients GM-CSF alteration ZDV/IFN dose level Further study GM-CSF alternate modification ZDV/IFN combination therapies AIDS patients